Data / Drug companies / Pai Holdings, LLC DBA Pai Pharma
Pai Holdings, LLC DBA Pai Pharma: 149 products in the FDA NDC directory, labeler code 0121
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Pai Holdings, LLC DBA Pai Pharma (labeler code 0121) lists 149 products in the FDA National Drug Code Directory, covering 74 finished drugs by generic name. By type: 110 prescription drugs, 39 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 12, 2026.
The request: Watch Pai Holdings, LLC DBA Pai Pharma (FDA labeler code 0121): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0121
- Products in commercial distribution
- 149
- Packages
- 213
- Finished drugs by generic name
- 74
- Prescription products
- 110
- Over the counter products
- 39
- Controlled substance products
- Schedule II 8, Schedule III 4, Schedule IV 5, Schedule V 11
- Flagged as original packager
- 123 of 123 products that carry the flag
- Started marketing in the last 12 months
- 24
- Products with a marketing end date set
- 2
- Earliest marketing start
- July 30, 1966
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 99 | 66.4% |
| Over the counter monograph drugs | 36 | 24.2% |
| Other unapproved drugs | 7 | 4.7% |
| New drug applications (NDA) | 6 | 4% |
| Authorized generics (NDA) | 1 | 0.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 110 | 73.8% |
| Over the counter drugs | 39 | 26.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 92 | 61.7% |
| Suspension | 24 | 16.1% |
| Liquid | 7 | 4.7% |
| Tablet | 4 | 2.7% |
| Injection | 3 | 2% |
| Injection, powder, for solution | 3 | 2% |
| Capsule | 2 | 1.3% |
| Rinse | 2 | 1.3% |
| Powder, for solution | 2 | 1.3% |
| Syrup | 2 | 1.3% |
| Patch | 1 | 0.7% |
| Ointment | 1 | 0.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Calcium chloride | 0121-1099 | Injection, solution | Generic drugs (ANDA) | October 12, 2026 |
| Glycerol Phenylbutyrate | 0121-1049 | Liquid | Generic drugs (ANDA) | October 12, 2026 |
| Chlorhexidine gluconate | 0121-1786 | Rinse | Generic drugs (ANDA) | August 25, 2026 |
| Propranolol Hydrochloride | 0121-4958 | Solution | Generic drugs (ANDA) | August 19, 2026 |
| Propranolol Hydrochloride | 0121-0958 | Solution | Generic drugs (ANDA) | August 19, 2026 |
| PrednisoLONE Sodium Phosphate | 0121-1100 | Solution | New drug applications (NDA) | June 26, 2026 |
| Pentamidine Isethionate | 0121-1102 | Inhalant | Generic drugs (ANDA) | June 12, 2026 |
| Pentamidine Isethionate | 0121-1101 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 12, 2026 |
| Ondansetron | 0121-4882 | Solution | Generic drugs (ANDA) | June 9, 2026 |
| Childrens Simethicone Drops | 0121-1095 | Liquid | Over the counter monograph drugs | June 8, 2026 |
| Infants Simethicone Drops | 0121-1094 | Liquid | Over the counter monograph drugs | June 8, 2026 |
| Voriconazole | 0121-1091 | Injection | Generic drugs (ANDA) | May 14, 2026 |
| Vancomycin hydrochloride | 0121-1033 | Capsule | Generic drugs (ANDA) | May 1, 2026 |
| Vancomycin hydrochloride | 0121-1032 | Capsule | Generic drugs (ANDA) | May 1, 2026 |
| Ondansetron | 0121-0882 | Solution | Generic drugs (ANDA) | April 20, 2026 |
| Lithium | 0121-4027 | Solution | Generic drugs (ANDA) | April 14, 2026 |
| Lithium | 0121-1027 | Solution | Generic drugs (ANDA) | April 14, 2026 |
| Benzocaine 20% | 0121-1077 | Solution | Over the counter monograph drugs | March 20, 2026 |
| Mupirocin | 0121-1076 | Ointment | Generic drugs (ANDA) | March 13, 2026 |
| Brivaracetam | 0121-1075 | Injection | Generic drugs (ANDA) | February 23, 2026 |
| Brivaracetam | 0121-1074 | Solution | Generic drugs (ANDA) | February 23, 2026 |
| Acetaminophen | 0121-3141 | Solution | Over the counter monograph drugs | December 9, 2025 |
| Acetaminophen | 0121-2094 | Solution | Over the counter monograph drugs | December 9, 2025 |
| Acetaminophen | 0121-1047 | Solution | Over the counter monograph drugs | December 9, 2025 |
| Megestrol Acetate | 0121-1038 | Suspension | Generic drugs (ANDA) | October 17, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.